Logo image of MGNX

MACROGENICS INC (MGNX) Stock Fundamental Analysis

NASDAQ:MGNX - Nasdaq - US5560991094 - Common Stock - Currency: USD

1.69  +0.05 (+3.05%)

After market: 1.69 0 (0%)

Fundamental Rating

3

We assign a fundamental rating of 3 out of 10 to MGNX. MGNX was compared to 551 industry peers in the Biotechnology industry. While MGNX seems to be doing ok healthwise, there are quite some concerns on its profitability. MGNX is valied quite expensively at the moment, while it does show a decent growth rate.


Dividend Valuation Growth Profitability Health

Quickly go to:

2

1. Profitability

1.1 Basic Checks

In the past year MGNX has reported negative net income.
In the past year MGNX has reported a negative cash flow from operations.
In the past 5 years MGNX always reported negative net income.
MGNX had a negative operating cash flow in each of the past 5 years.
MGNX Yearly Net Income VS EBIT VS OCF VS FCFMGNX Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -50M -100M -150M -200M

1.2 Ratios

MGNX has a Return On Assets of -24.85%. This is in the better half of the industry: MGNX outperforms 73.14% of its industry peers.
MGNX has a Return On Equity (-70.54%) which is in line with its industry peers.
Industry RankSector Rank
ROA -24.85%
ROE -70.54%
ROIC N/A
ROA(3y)-23.78%
ROA(5y)-33.18%
ROE(3y)-49.33%
ROE(5y)-55.24%
ROIC(3y)N/A
ROIC(5y)N/A
MGNX Yearly ROA, ROE, ROICMGNX Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -20 -40 -60 -80

1.3 Margins

MGNX has a better Gross Margin (89.88%) than 92.56% of its industry peers.
In the last couple of years the Gross Margin of MGNX has declined.
MGNX does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 89.88%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-1.7%
GM growth 5YN/A
MGNX Yearly Profit, Operating, Gross MarginsMGNX Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -100 -200

More info and screens

5

2. Health

2.1 Basic Checks

MGNX does not have a ROIC to compare to the WACC, probably because it is not profitable.
MGNX has more shares outstanding than it did 1 year ago.
Compared to 5 years ago, MGNX has more shares outstanding
MGNX has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
MGNX Yearly Shares OutstandingMGNX Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M
MGNX Yearly Total Debt VS Total AssetsMGNX Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M

2.2 Solvency

Based on the Altman-Z score of -7.22, we must say that MGNX is in the distress zone and has some risk of bankruptcy.
With a Altman-Z score value of -7.22, MGNX is not doing good in the industry: 67.33% of the companies in the same industry are doing better.
There is no outstanding debt for MGNX. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -7.22
ROIC/WACCN/A
WACC10.86%
MGNX Yearly LT Debt VS Equity VS FCFMGNX Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 100M -100M 200M 300M

2.3 Liquidity

A Current Ratio of 3.28 indicates that MGNX has no problem at all paying its short term obligations.
MGNX has a Current ratio of 3.28. This is in the lower half of the industry: MGNX underperforms 61.16% of its industry peers.
A Quick Ratio of 3.11 indicates that MGNX has no problem at all paying its short term obligations.
The Quick ratio of MGNX (3.11) is worse than 61.71% of its industry peers.
Industry RankSector Rank
Current Ratio 3.28
Quick Ratio 3.11
MGNX Yearly Current Assets VS Current LiabilitesMGNX Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M

More info and screens

4

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 55.50% over the past year.
Looking at the last year, MGNX shows a very strong growth in Revenue. The Revenue has grown by 255.58%.
The Revenue has been growing by 18.49% on average over the past years. This is quite good.
EPS 1Y (TTM)55.5%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%22.62%
Revenue 1Y (TTM)255.58%
Revenue growth 3Y24.67%
Revenue growth 5Y18.49%
Sales Q2Q%44.9%

3.2 Future

The Earnings Per Share is expected to grow by 17.06% on average over the next years. This is quite good.
The Revenue is expected to decrease by -2.68% on average over the next years.
EPS Next Y-108.77%
EPS Next 2Y-27.81%
EPS Next 3Y-25.89%
EPS Next 5Y17.06%
Revenue Next Year-77.54%
Revenue Next 2Y-58.51%
Revenue Next 3Y-31.82%
Revenue Next 5Y-2.68%

3.3 Evolution

When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
MGNX Yearly Revenue VS EstimatesMGNX Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 100M 200M 300M 400M 500M
MGNX Yearly EPS VS EstimatesMGNX Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 0 -2 -4

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for MGNX. In the last year negative earnings were reported.
Also next year MGNX is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
MGNX Price Earnings VS Forward Price EarningsMGNX Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
MGNX Per share dataMGNX EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 1 -1 2

4.3 Compensation for Growth

MGNX's earnings are expected to decrease with -25.89% in the coming years. This may justify a cheaper valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-27.81%
EPS Next 3Y-25.89%

More info and screens

0

5. Dividend

5.1 Amount

MGNX does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

MACROGENICS INC

NASDAQ:MGNX (8/5/2025, 6:00:40 PM)

After market: 1.69 0 (0%)

1.69

+0.05 (+3.05%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)05-13 2025-05-13/amc
Earnings (Next)08-12 2025-08-12
Inst Owners80.77%
Inst Owner Change-0.98%
Ins Owners0.92%
Ins Owner Change2.06%
Market Cap106.62M
Analysts75.38
Price Target4.28 (153.25%)
Short Float %7.03%
Short Ratio2.9
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)31.15%
Min EPS beat(2)18.49%
Max EPS beat(2)43.8%
EPS beat(4)3
Avg EPS beat(4)82.57%
Min EPS beat(4)-48.21%
Max EPS beat(4)316.2%
EPS beat(8)4
Avg EPS beat(8)35.14%
EPS beat(12)6
Avg EPS beat(12)15.05%
EPS beat(16)6
Avg EPS beat(16)5.02%
Revenue beat(2)1
Avg Revenue beat(2)33.78%
Min Revenue beat(2)-42.16%
Max Revenue beat(2)109.73%
Revenue beat(4)2
Avg Revenue beat(4)14.89%
Min Revenue beat(4)-50.61%
Max Revenue beat(4)109.73%
Revenue beat(8)2
Avg Revenue beat(8)-22.78%
Revenue beat(12)5
Avg Revenue beat(12)-10.55%
Revenue beat(16)6
Avg Revenue beat(16)-16.61%
PT rev (1m)0%
PT rev (3m)-27.59%
EPS NQ rev (1m)0%
EPS NQ rev (3m)25.52%
EPS NY rev (1m)0%
EPS NY rev (3m)23.61%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)23.2%
Revenue NY rev (1m)0%
Revenue NY rev (3m)-1.96%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 0.69
P/FCF N/A
P/OCF N/A
P/B 1.35
P/tB 1.35
EV/EBITDA N/A
EPS(TTM)-0.89
EYN/A
EPS(NY)-1.76
Fwd EYN/A
FCF(TTM)-1.15
FCFYN/A
OCF(TTM)-1.1
OCFYN/A
SpS2.44
BVpS1.25
TBVpS1.25
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -24.85%
ROE -70.54%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 89.88%
FCFM N/A
ROA(3y)-23.78%
ROA(5y)-33.18%
ROE(3y)-49.33%
ROE(5y)-55.24%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-1.7%
GM growth 5YN/A
F-Score3
Asset Turnover0.69
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 37.16%
Cap/Sales 1.8%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 3.28
Quick Ratio 3.11
Altman-Z -7.22
F-Score3
WACC10.86%
ROIC/WACCN/A
Cap/Depr(3y)32.65%
Cap/Depr(5y)40.48%
Cap/Sales(3y)2.62%
Cap/Sales(5y)4.3%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)55.5%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%22.62%
EPS Next Y-108.77%
EPS Next 2Y-27.81%
EPS Next 3Y-25.89%
EPS Next 5Y17.06%
Revenue 1Y (TTM)255.58%
Revenue growth 3Y24.67%
Revenue growth 5Y18.49%
Sales Q2Q%44.9%
Revenue Next Year-77.54%
Revenue Next 2Y-58.51%
Revenue Next 3Y-31.82%
Revenue Next 5Y-2.68%
EBIT growth 1Y45.8%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-14.54%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-62.14%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-65.41%
OCF growth 3YN/A
OCF growth 5YN/A